FDA's Orphan Drugs Program
Development of drugs for rare diseasesIncentives for Rare Disease Drug Development
The FDA’s Orphan Drug Program was established to encourage the development of drugs for rare diseases that affect fewer than 200,000 people in the U.S.
Because these diseases often lack market incentives due to small patient populations, the FDA offers benefits and protections to make developing these therapies more feasible for pharmaceutical companies.
By offering incentives such as market exclusivity for seven years, tax credits for clinical trials, and waived user fees, the program helps mitigate the financial risks for companies developing treatments for these conditions. Additionally, the program provides guidance and grants to support research and development efforts.
Since its inception in 1983, the program has led to the approval of over 1,100 orphan drugs, significantly improving treatment options for patients with rare diseases and conditions that previously lacked effective therapies.
Key Program Goals
- Stimulate research and development of drugs for rare diseases
- Ensure patients with rare conditions have access to safe and effective treatments
- Reduce the economic and regulatory barriers that discourage investment
What Qualifies a Drug for Orphan Status?
To qualify:
- The drug must treat, diagnose, or prevent a disease or condition affecting fewer than 200,000 people in the U.S., or
- If the population is larger, the sponsor must show there is no reasonable expectation of recovering development costs through U.S. sales.
Benefits of Orphan Drug Designation
When a product is granted orphan drug status, the sponsor receives several incentives:
| Benefit | Description |
| 7 Years of Market Exclusivity | After approval, the FDA will not approve a similar drug for the same indication |
| Tax Credits | Up to 25% of qualified clinical trial costs |
| Waived User Fees | FDA application and annual product fees may be waived |
| Assistance from FDA | Access to the Orphan Products Grants Program and guidance on study design |
| Eligibility for Grants | Competitive grant funding for clinical trials through the Office of Orphan Products Development (OOPD) |
Process Overview
- Sponsor applies for Orphan Drug Designation before submitting an NDA/BLA
- FDA reviews the application and grants designation if criteria are met
- After successful clinical trials, sponsor submits a marketing application
- If approved, the 7-year exclusivity and other incentives apply
Impact of the Program
- Over 1,100 orphan drugs have been approved since 1983
- Conditions treated range from rare cancers to genetic disorders, autoimmune diseases, and metabolic syndromes
- Has dramatically increased investment in previously neglected diseases
Examples of Orphan Drug Approvals
- Spinraza (nusinersen) – for spinal muscular atrophy
- Luxturna (voretigene neparvovec) – for inherited retinal dystrophy
- Zolgensma (onasemnogene abeparvovec) – gene therapy for SMA
- Lynparza (olaparib) – for BRCA-mutated ovarian cancer
- Lynozyfic (linvoseltamab-gcpt) – for relapsed/refractory multiple myeloma (recent)
Summary
| Feature | Orphan Drug Program |
| Target Diseases | Rare (≤200,000 U.S. patients) |
| Lead FDA Office | Office of Orphan Products Development (OOPD) |
| Key Benefits | Market exclusivity, tax credits, fee waivers |
| Approval Path | NDA/BLA after orphan designation |
| Major Goal |
Encourage R&D for underserved patient populations |
Read more about the program.
Read about the Orphan Drugs Program on the FDA website.
SonarMed Inc Recalls Airway Acoustic Sensors
Urgent Class I Recall Notice SonarMed Inc. has issued a Class I recall for its Airway acoustic sensors due to a critical issue that could lead to serious health consequences for patients. The U.S. Food and Drug Administration (FDA) has identified this as the most...
DeRoyal Industries, Inc. Recalls Tracecarts
Urgent Class I Recall Notice DeRoyal Industries, Inc. has issued an urgent recall notice for certain Tracecarts containing 16FR Urine Meter Foley under recall by Nurse Assist. Identified by the FDA as a Class I recall, the most serious type, the use of these devices...
Class I Recall for Stay-Safe Catheter Extension Sets and Adapters
Urgent Class I Recall Notice FDA has issued a Class I recall – the most serious type – for certain medical devices manufactured by Fresenius Medical Care. The recall concerns Stay-Safe Catheter Extension Sets and Stay-Safe/Luer Lock Adapters, pivotal components used...